TY - JOUR
T1 - Antibiotic Treatment Pipeline for Clostridioides difficile Infection (CDI)
T2 - A Wide Array of Narrow-Spectrum Agents
AU - Carlson, T. J.
AU - Gonzales-Luna, A. J.
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Purpose of Review: Clostridioides difficile infection (CDI) represents a major burden on the U.S. healthcare system. Despite the U.S. Food and Drug Administration (FDA) approval of fidaxomicin in 2011, observed rates of clinical cure and CDI recurrence suggest there is room to improve. As a result, there are many antibiotic treatments in the developmental pipeline for CDI. The purpose of this focused review is to summarize these antibiotic therapies in all stages of development. Recent Findings: Here, we discuss 10 antibiotics in development, including three that have completed phase II trials, five in phase II trials, and two still undergoing preclinical trials. Summary: The antibiotic treatment pipeline for CDI contains a plethora of narrow-spectrum agents with unique mechanisms of action and potent activity against C. difficile. Only ridinilazole, LFF571, and ramoplanin have completed phase II trials, and ridinilazole is the only antibiotic to begin recruitment for a phase III trial. While the future of CDI treatment appears bright, the healthcare community will have to await the results from phase III trials.
AB - Purpose of Review: Clostridioides difficile infection (CDI) represents a major burden on the U.S. healthcare system. Despite the U.S. Food and Drug Administration (FDA) approval of fidaxomicin in 2011, observed rates of clinical cure and CDI recurrence suggest there is room to improve. As a result, there are many antibiotic treatments in the developmental pipeline for CDI. The purpose of this focused review is to summarize these antibiotic therapies in all stages of development. Recent Findings: Here, we discuss 10 antibiotics in development, including three that have completed phase II trials, five in phase II trials, and two still undergoing preclinical trials. Summary: The antibiotic treatment pipeline for CDI contains a plethora of narrow-spectrum agents with unique mechanisms of action and potent activity against C. difficile. Only ridinilazole, LFF571, and ramoplanin have completed phase II trials, and ridinilazole is the only antibiotic to begin recruitment for a phase III trial. While the future of CDI treatment appears bright, the healthcare community will have to await the results from phase III trials.
KW - Antibiotic
KW - Clinical trial
KW - Clostridium difficile
KW - Drug pipeline
KW - Microbiome
KW - Narrow spectrum
UR - http://www.scopus.com/inward/record.url?scp=85086223052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85086223052&partnerID=8YFLogxK
U2 - 10.1007/s11908-020-00730-1
DO - 10.1007/s11908-020-00730-1
M3 - Review article
AN - SCOPUS:85086223052
SN - 1523-3847
VL - 22
JO - Current Infectious Disease Reports
JF - Current Infectious Disease Reports
IS - 8
M1 - 20
ER -